Uric Acid in Metabolic and Cerebrovascular Disorders: A Review

Curr Vasc Pharmacol. 2020;18(6):610-618. doi: 10.2174/1570161118666191217123930.

Abstract

Background: Several studies showed a close link between metabolic syndrome (MetS), type 2 diabetes (T2DM) and cerebrovascular diseases. There is considerable debate regarding the role of uric acid (UA) as a risk factor in these conditions.

Objective: The aim of this narrative review is to discuss the links between UA, MetS, T2DM and cerebrovascular disease.

Methods: An extensive review has been conducted based on the scientific literature published in English, and indexed in MEDLINE (through PubMed), EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and Google Scholar from January to May 2019. Additional relevant studies published after the initial review were also considered during the period of June 2019-October 2019, during which, this manuscript was written. The Mesh Terms considered were: uric acid, antioxidant, oxidant, metabolic syndrome, diabetes, cerebrovascular diseases, stroke, haemorrhagic stroke, neurocognitive disorders, and their combinations.

Results: The literature review shows a dose-dependent inflammatory action of UA, which occurs with serum concentrations >4 mg/dl (>0.24 mmol/l), representing one of the contributors to the chronic inflammatory process that underlies metabolic and cerebrovascular diseases.

Conclusion: UA, which is associated with arterial hypertension and cardiovascular diseases, represents one of the indicators of oxidative homeostasis. Increasing concentrations represent a status of active inflammation which is observed with metabolic and cerebrovascular diseases.

Keywords: Uric acid; cerebrovascular events; metabolic syndrome; neurocognitive disorders; stroke; type 2 diabetes.

Publication types

  • Review

MeSH terms

  • Animals
  • Biomarkers / blood
  • Blood Glucose / metabolism*
  • Cardiometabolic Risk Factors
  • Cerebrovascular Disorders / blood*
  • Cerebrovascular Disorders / etiology
  • Cerebrovascular Disorders / physiopathology
  • Diabetes Mellitus, Type 2 / blood*
  • Diabetes Mellitus, Type 2 / etiology
  • Diabetes Mellitus, Type 2 / physiopathology
  • Humans
  • Hyperuricemia / blood*
  • Hyperuricemia / complications
  • Metabolic Syndrome / blood*
  • Metabolic Syndrome / etiology
  • Metabolic Syndrome / physiopathology
  • Prognosis
  • Risk Assessment
  • Uric Acid / blood*

Substances

  • Biomarkers
  • Blood Glucose
  • Uric Acid